Takeda and Denali pen neurodegenerative disease alliance
Newly public biotech Denali Therapeutics Inc. granted Takeda Pharmaceutical Co. Ltd. options to license exclusive global rights to three of its early-stage programs in the neurodegenerative disease space.
- Large Molecule
- Includes Equity
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email [email protected]
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.